Straits Times Index
3,312.93 -9.15 (-0.28%) Nikkei
39,163.82 +125.66 (+0.32%) Hang Seng
18,046.86 -320.09 (-1.74%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
68,227.54 -1,505.10 (-2.16%) CMC Crypto 200
1,423.33 -23.34 (-1.61%)
LLY Jan 2026 490.000 call
| Previous close | 317.70 |
| Open | 317.70 |
| Bid | 335.00 |
| Ask | 344.00 |
| Strike | 490.00 |
| Expiry date | 2026-01-16 |
| Day's range | 317.70 - 317.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
- Yahoo Finance Video
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
A US Food and Drug Administration (FDA) panel voted unanimously 11-0 to recommend the approval of Eli Lilly's (LLY) Alzheimer's drug, donanemab. Yahoo Finance's Anjalee Khemlani reports more on the story and the drug's ability to slow cognitive decline. Read more about donanemab here. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
ZacksApple Joins A.I. Race; Lilly Thumbs-Up on Alzheimer's Drug
Considering how many Apple products there are out there in the world at this time, a high number of them will soon be accessing A.I. from an Apple device.
Associated Press FinanceAlzheimer's drug that can slow disease gets backing from FDA advisers
A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease. Food and Drug Administration advisers voted unanimously that the drug's ability to slow the disease outweighs its risks, including side effects like brain swelling and bleeding that will have to be monitored. The FDA will make the final decision on approval later this year.
